Abstract
Purpose
Squamous cell anal carcinoma (SCC) is an uncommon disease comprising only 1–5% of all intestinal tumours. SCC is now considered the prototype for the successful application of conservative treatment as chemoradiation instead of aggressive surgery. The EGFR status and k-ras mutations in SCC of the anal canal has not been well investigated. The purpose of our evaluation was to give information about this issue.
Methods
From June 1999 to December 2008, 32 patients affected by SCC were treated in our institution with chemotherapy containing fluoropyrimidine and platinum salt concomitant with pelvic radiotherapy. Immunohistochemistry for EGFR and k-ras mutation was retrospectively evaluated.
Results
Twenty-six specimens were considered evaluable for biological objectives: K-ras mutation was performed in all cases, while EGFR in 12. In all cases of our series wild-type K-ras was observed.
Conclusions
Such information is, in our knowledge, the first reported in literature on this setting. This observation previously reported in other tumours has supported the effective use of EGFR-inhibitors in recurrent or metastatic disease. This observation could support the role of EGFR-inhibitors in the treatment of SCC.
This is a preview of subscription content, log in via an institution to check access.
References
Daling JR, Madeleine MM, Johnsson LG et al (2004) Human papillomavirus, smoking, and sexual practices in the aetiology of anal cancer. Cancer 101:270–280
Fuchschuber PR, Rodriguez-Bigas M, Weber T et al (1997) Anal canal and perianal epidermoid cancers. J Am Coll Surg 185(5):494–505
Ruíz-Godoy RLM, Garcia-Cuellar CM, Herrera González NE et al (2006) Mutational analysis of K-ras and Ras protein expression in larynx squamous cell carcinoma. J Exp Clin Cancer Res 25(1):73–78
Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27(5):663–671
Alvarez G, Perry A, Tan BR et al (2006) Expression of epidermal growth factor receptor in squamous cell carcinoma of anal canal is independent of gene amplification. Modern Pathol 19:942–949
Le LH, Chetty R, Moore MJ (2005) Epidermal growth receptor expression in anal canal carcinoma. Am J Clin Pathol 124:20–23
Ajani J, Wang X, Izzo J et al (2009) Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. Dig Dis Sci 28 Apr (Epub ahead of print)
Atkins D, Reiffen KA, Tegtmeier CL et al (2004) Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52(7):893–901
Hiorn LR, Scholefield HJ, Palmer JG et al (1990) Ki-ras oncogene mutations in non-HPV-associated anal carcinoma. J Pathol 161:99–103
Phan LK, Hoff PM (2007) Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma. Report of a case. Dis Colon Rectum 50(3):395–398
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zampino, M.G., Magni, E., Sonzogni, A. et al. K-ras status in squamous cell anal carcinoma (SCC): it’s time for target-oriented treatment?. Cancer Chemother Pharmacol 65, 197–199 (2009). https://doi.org/10.1007/s00280-009-1117-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-009-1117-3